Mesoblast’s (NASDAQ:MESO) remestemcel-L will be evaluated in a placebo-controlled trial in 240 patients with acute respiratory distress syndrome (ARDS) caused by COVID-19.
This Phase 2/3 trial will be conducted as a
public-private partnership in collaboration with the Cardiothoracic
Surgical Trials Network, established by the U.S. National Institutes of
Health’s National Heart, Lung and Blood Institute as a flexible platform
for conducting collaborative trials.
https://seekingalpha.com/news/3559604-mesoblast-on-go-study-of-remestemcel-l-in-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.